Are you checking for any specific mutations in NSCLC that suggest resistance to checkpoint inhibitors?
Are there any biomarkers that would affect your decision for first line PD-1 therapy (including but not limited to STK11)?
Community PollStarted
Are there any biomarkers that would affect your decision for first line PD-1 therapy?
16 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University Hospitals Seidman Cancer Center and Case Western Reserve University
Answered on
There has been a significant amount of data both published and presented concerning the various genomic markers (mutations) that may predict for response or the absence of response to immune checkpoint inhibitor. However, in clinical practice they are not commonly used as most patients are receiving...
Join for free or sign in to see the full answer